Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0503 • ACR Convergence 2020
Targeted Metabolomic Profiling and Prediction of Cardiovascular Events: A Prospective Study of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis and psoriasis, collectively termed psoriatic disease (PsD), are associated with increased cardiovascular (CV) risk. Metabolites comprise biomarkers that may add predictive value…
Abstract Number: 0889 • ACR Convergence 2020
Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies
Christopher Ritchlin¹, Alan Kivitz², Peter Nash³, Renato Calheiros⁴, Xiangyi Meng⁵, Corine Gaillez⁶, Bruce Kirkham⁷ and Iain McInnes⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) can progress quickly and lead to irreversible damage within 2 years of initial assessment if not treated.1 Secukinumab (SEC), a selective…
Abstract Number: 1027 • ACR Convergence 2020
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2017
Sofia Exarchou¹, Johan K. Wallman², Daniela Di Giuseppe³, Gerd-Marie Alenius⁴, Eva Klingberg⁵, Valgerdur Sigurdardottir⁶, Sara Wedrén⁷, Ulf Lindström⁸, Carl Turesson⁹, Lennart T.H. Jacobsson¹⁰ and Johan Askling³, ¹Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ²Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden. Department of Rheumatology, Skåne University Hospital, Lund, Sweden., Lund, Sweden, ³Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Rheumatology, Norrland University Hospital, Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, Umeå, Sweden, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Vastra Gotaland, Sweden, ⁶Rheumatology, Falun Hospital, Centre for Clinical Research Dalarna, Uppsala University, Falun, Sweden, Falun, Sweden, ⁷Rheumatology, Karolinska University Hospital, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁸Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden, ¹⁰Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden
Background/Purpose: Reported prevalence estimates of psoriatic arthritis (PsA) vary considerably, with few nationwide figures. This study aimed to estimate the prevalence of PsA among adults…
Abstract Number: 1343 • ACR Convergence 2020
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
Philip Mease¹, Pamela Young², David Gruben³, Lara Fallon⁴, Rebecca Germino⁵ and Arthur Kavanaugh⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Montreal, QC, Canada, ⁵Pfizer Inc, New York, NY, ⁶UC San Diego Health System, San Diego, CA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). It was approved in the US in December 2017 for…
Abstract Number: 1373 • ACR Convergence 2020
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
Alessandra Nerviani¹, Marie-Astrid Boutet¹, Wang Sin Gina Tan¹, Katriona Goldmann¹, Nirupam Purkayastha¹, Tamas Lajtos¹, Rebecca Hands¹, Myles Lewis¹, Stephen Kelly² and Costantino Pitzalis³, ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Mile End Hospital, Barts Health NHS Trust, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom
Background/Purpose: PsA is a chronic heterogeneous inflammatory condition affecting up to 30% of patients with skin and/or nail psoriasis and the IL-23/IL-17 axis is believed…
Abstract Number: 1849 • ACR Convergence 2020
Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study
Jesus Miguens Blanco¹, Uma Selvarajah¹, Zhigang Lui¹, Benjamin Mullish¹, James Alexander¹, Julie McDonald², Sonya Abraham¹ and Julian Marchesi¹, ¹Imperial College London, London, United Kingdom, ²Imperial College London, London
Background/Purpose: Perturbations of the gut microbiota have been associated with Psoriatic Arthritis (PsA), a chronic inflammatory disease. We aim to test the microbiome-metabolic interface of…
Abstract Number: 0308 • ACR Convergence 2020
Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study
Paras Karmacharya¹, Kerry Wright², Sara J. Achenbach³, Delamo Bekele², Cynthia Crowson⁴, Alexis Ogdie⁵, Ali Duarte-Garcia², Floranne C. Ernste³, Megha M. Tollefson¹ and John Davis², ¹Mayo Clinic, Rochester MN, ROCHESTER, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease which may precede, occur concurrently or after the development of psoriasis. In order to better understand the…
Abstract Number: 0324 • ACR Convergence 2020
Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials
Courtney Stull¹, Soumya Reddy², M. Elaine Husni³, Jose Scher⁴, Ethan Craig¹, Jessica Walsh⁵ and Alexis Ogdie¹, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³Cleveland Clinic, Cleveland, OH, ⁴NYU School of Medicine, New York City, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition; this presents a challenge in how to best measure disease activity for all patients. While several outcome…
Abstract Number: 0342 • ACR Convergence 2020
Multimorbidity Clusters in Psoriatic Arthritis: A Population-Based Study
Paras Karmacharya¹, Dilli Poudel², Cynthia Crowson³, John Davis⁴, Kerry Wright⁴ and Alexis Ogdie², ¹Mayo Clinic, Rochester MN, ROCHESTER, MN, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Psoriatic arthritis (PsA) patients have a higher prevalence of cardiometabolic and other morbidities compared to the general population. Studies suggest that a single clinical…
Abstract Number: 0367 • ACR Convergence 2020
Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
Stefan Siebert¹, Iain McInnes², Matthew J. Loza³, Keying Ma⁴, Karen Leander⁴, Vani Lakshminarayanan⁴, Carol Franks⁴, Philip Cooper⁴ and Kristen Sweet⁴, ¹University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Janssen Research & Development, LLC, Spring House, ⁴Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS), an IL-23 inhibitor monoclonal antibody (MAb) that specifically binds the IL-23p19 subunit, demonstrated efficacy compared to placebo (PBO) in reducing skin &…
Abstract Number: 0504 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Mark Genovese¹, Apinya Lertratanakul², Jaclyn K Anderson², Kim Papp³, William Tillett⁴, Filip Van den Bosch⁵, Shigeyoshi Tsuji⁶, Eva Dokoupilova⁷, Mauro Keiserman⁸, Xin Wang², Sheng Zhong², Patrick Zueger², Aileen Pangan⁹ and Philip Mease¹⁰, ¹Stanford University Medical Center, Palo Alto, CA, ²AbbVie Inc., North Chicago, IL, ³Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁷Uherske Hradiste and University of Veterinary and Pharmaceutical Sciences,, Brno, Czech Republic, ⁸Pontificial Catholic University, Porto Alegre, Brazil, ⁹Abbvie Inc., La Grange, IL, ¹⁰Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment…
Abstract Number: 0891 • ACR Convergence 2020
Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
Kristian Reich¹, Jan Dutz², Peter Foley³, Diamant Thaçi⁴, Ron Vender⁵, Michael Song⁶, Megan Miller⁶, Yin Yu⁶, Shu Li⁷, Yaung-Kaung Shen⁶ and April W. Armstrong⁸, ¹Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany, ²Vancouver General Hospital, Vancouver, Canada, ³University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, Australia, ⁴Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁵McMaster University, Hamilton, Canada, ⁶Janssen Research & Development, LLC, Spring House, ⁷Janssen Scientific Affairs, LLC, Horsham, ⁸Keck School of Medicine of University of Southern California, Los Angeles, CA
Background/Purpose: Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1 and VOYAGE 2 are two ongoing Phase 3, randomized, double-blind,…
Abstract Number: 1030 • ACR Convergence 2020
Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy
Theresa Hunter¹, Chi Nguyen², Julie Birt³, Joseph Smith², Mingyang Shan³, Hiangkiat Tan², Jeffrey Lisse³ and Keith Isenberg⁴, ¹Eli Lilly and Company, Indianapolis, ²Healthcore, Inc, Wilmington, DE, ³Eli Lilly and Company, Indianapolis, IN, ⁴Anthem, Inc, Indianapolis, IN
Background/Purpose: Pain is a common symptom among ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and can be debilitating, making pain management an integral part…
Abstract Number: 1344 • ACR Convergence 2020
Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
Christopher Ritchlin¹, Philip Helliwell², Wolf-Henning Boehncke³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Ramanand Subramanian⁶, Xie Xu⁷, Shihong Sheng⁶, Yusang Jiang⁶, Bei Zhou⁶ and Atul Deodhar⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Geneva University Hospitals, Geneva, Switzerland, ⁴Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, San Marcos, CA, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis (PsO). At Week 24 of the…
Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Bruce Kirkham¹, Peter Nash², Sandra Navarra³, Erhard Quebe-Fehling⁴, Corine Gaillez⁴, Carlos Sastre⁴ and Philip Mease⁵, ¹Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Santo Tomas, Manila, Philippines, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].